(Q38001453)

26 August 2017

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor (English)

1 reference

26 August 2017

1 reference

1 reference

Renli Teng

1

1 reference

26 August 2017

1 May 2012

1 reference

26 August 2017

14

1 reference

Clinical Pharmacokinetics

inferred from page(s)

published in

1 reference

26 August 2017

51

1 reference

26 August 2017

5

1 reference

26 August 2017

305-318

1 reference

https://scigraph.springernature.com/pub.10.2165/11630960-000000000-00000

26 August 2017

0 references

cites work

Acute coronary syndromes: diagnosis and management, part I

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Rev

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the M

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Effect of Heparin and Heparin Fractions on Platelet Aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

P2Y1 gene polymorphism and ADP-induced platelet response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11630960-000000000-00000

The Platelet Aggregating Effect of Eight Commercial Heparins

21 January 2018

1 reference

12 December 2020

Burden of disease: medical and economic impact of acute coronary syndromes

1 reference

12 December 2020

Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model

1 reference

12 December 2020

Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

1 reference

12 December 2020

Platelet response heterogeneity in thrombus formation.

1 reference

12 December 2020

Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets

1 reference

12 December 2020

Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.

1 reference

12 December 2020

Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.

1 reference

12 December 2020

Differential effects of anticoagulants on the activation of platelets ex vivo

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment

1 reference

12 December 2020

Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.

1 reference

12 December 2020

The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo.

1 reference

12 December 2020

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

1 reference

12 December 2020

Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers

1 reference

12 December 2020

Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment

1 reference

12 December 2020

10.2165/11630960-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22489610

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22489610